Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Undevia · SciRah

Researcher profile · Semantic Scholar

S. Undevia

Share profile

S. Undevia — researcher profile on SciRah

h-index: 23
Works: 61
Citations: 3,462

Most-cited papers

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
F. Innocenti, S. Undevia, L. Iyer, Pei-Xian Chen +8 more
2004Journal of Clinical Oncology997 citations Open access
Semantic Scholar
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
R. Maki, D. D'Adamo, M. Keohan, M. Saulle +16 more
2009Journal of Clinical Oncology546 citations Open access
Semantic Scholar
Pharmacokinetic variability of anticancer agents
S. Undevia, G. Gomez-Abuin, M. Ratain
2005Nature Reviews. Cancer242 citations
Semantic Scholar
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
Gary K. Schwartz, W. Tap, L. Qin, M. Livingston +24 more
2013The Lancet Oncology178 citations Open access
Semantic Scholar
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment
M. Maitland, K. Kasza, T. Karrison, K. Moshier +6 more
2009Clinical Cancer Research171 citations Open access
Semantic Scholar
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
F. Innocenti, R. Schilsky, J. Ramírez, L. Janisch +10 more
2014Journal of Clinical Oncology143 citations Open access
Semantic Scholar
Primary Tumor Necrosis Predicts Distant Control in Locally Advanced Soft Tissue Sarcomas Following Preoperative Concurrent Chemoradiotherapy
D. Macdermed, L. Miller, T. Peabody, M. A. Simon +5 more
2009International Journal of Radiation Oncology, Biology, Physics98 citations Open access
Semantic Scholar
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma
W. Chow, P. Frankel, C. Ruel, D. Araujo +5 more
2019Cancer81 citations Open access
Semantic Scholar
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
S. Undevia, H. Kindler, L. Janisch, S. C. Olson +5 more
2004Annals of Oncology74 citations Open access
Semantic Scholar
Phase 1 Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
E. Cohen, Ke-Hua Wu, C. Hartford, M. Kocherginsky +12 more
2012Clinical Cancer Research68 citations Open access
Semantic Scholar
Histologic response of dose‐intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high‐risk soft tissue sarcomas
C. Ryan, Anthony G. Montag, J. Hosenpud, B. Samuels +6 more
2008Cancer67 citations
Semantic Scholar
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours
S. Undevia, F. Innocenti, J. Ramírez, L. House +6 more
2008European Journal of Cancer58 citations Open access
Semantic Scholar
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
F. Innocenti, S. Undevia, J. Ramírez, S. Mani +4 more
2004Clinical pharmacology and therapy55 citations
Semantic Scholar
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Sarcomatosis
G. Salti, Luay D Ailabouni, S. Undevia
2012Annals of Surgical Oncology54 citations
Semantic Scholar
Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway.
M. Maitland, K. Moshier, J. Imperial, K. Kasza +6 more
2006Journal of Clinical Oncology49 citations
Semantic Scholar
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
Robin L. Jones, M. Ratain, Peter J. O'Dwyer, L. Siu +26 more
2017European Journal of Cancer47 citations Open access
Semantic Scholar
Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies
T. Gangadhar, E. Cohen, Ke-Hua Wu, L. Janisch +8 more
2011Clinical Cancer Research46 citations Open access
Semantic Scholar
Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies
C. Ryan, N. Vogelzang, E. Vokes, H. Kindler +6 more
2004Clinical Cancer Research40 citations Open access
Semantic Scholar
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
S. Undevia, N. Vogelzang, A. Mauer, L. Janisch +2 more
2004Investigational new drugs36 citations
Semantic Scholar
Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.
G. Schwartz, R. Maki, M. Ratain, S. Undevia +14 more
2011Journal of Clinical Oncology32 citations
Semantic Scholar
A Phase I Study of Continuous Infusion Cilengitide in Patients with Solid Tumors
P. H. O'Donnell, S. Undevia, Walter M. Stadler, Theodore Karrison +3 more
2010Investigational new drugs31 citations Open access
Semantic Scholar
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease
P. O'Donnell, A. Artz, S. Undevia, R. Pai +9 more
2010Leukemia and Lymphoma31 citations Open access
Semantic Scholar
Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060)
D. D'Adamo, M. Keohan, S. Schuetze, S. Undevia +6 more
200731 citations
Semantic Scholar
Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060
R. Maki, M. Keohan, S. Undevia, M. Livingston +6 more
200823 citations
Semantic Scholar
Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2
F. Innocenti, S. Undevia, Pei-Xian Chen, Soma Das +5 more
200423 citations
Semantic Scholar
The Quinoxaline Antitumor Agent (R+)XK469 Inhibits Neuroblastoma Tumor Growth
N. Kakodkar, Radhika Peddinti, M. Kletzel, Yu-Feng Tian +7 more
2011Pediatric Blood & Cancer22 citations Open access
Semantic Scholar
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
E. Posadas, S. Undevia, E. Manchen, J. Wade +4 more
2007Journal of Clinical Oncology22 citations Open access
Semantic Scholar
Correction of the galactocerebrosidase deficiency in globoid cell leukodystrophy-cultured cells by SL3-3 retroviral-mediated gene transfer.
M. Gama Sosa, R. De Gasperi, S. Undevia, J. Yeretsian +3 more
1996Biochemical and Biophysical Research Communications - BBRC21 citations Open access
Semantic Scholar
Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781
S. Undevia, L. Janisch, R. Schilsky, D. Loury +6 more
200818 citations
Semantic Scholar
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
R. Chugh, Kent A. Griffith, Elizabeth J. Davis, Dafydd G. Thomas +6 more
2015Annals of Oncology17 citations Open access
Semantic Scholar
Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes
F. Innocenti, S. Undevia, G. Rosner, L. Xiao +6 more
200517 citations
Semantic Scholar
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
M. Ratain, David Geary, S. Undevia, C. Coronado +4 more
2015Investigational new drugs15 citations
Semantic Scholar
Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetic (PK) variability: Evidence for a functional variant of ABCC2.
F. Innocenti, S. Undevia, P.-X. Chen, S. Das +5 more
2004Journal of Clinical Oncology13 citations
Semantic Scholar
Spinal Cord Metastasis of a Non-neurofibromatosis Type-1 Malignant Peripheral Nerve Sheath Tumor: An Unusual Manifestation of a Rare Tumor
W. Baek, P. Pytel, S. Undevia, Helene Rubeiz
2005Journal of Neuro-Oncology12 citations
Semantic Scholar
An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population
B. Polite, Toni M Cipriano-Steffens, F. Hlubocky, J. Dignam +8 more
2017Journal of Racial and Ethnic Health Disparities11 citations
Semantic Scholar
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
W. Stock, S. Undevia, C. Bivins, F. Ravandi +13 more
2008Investigational new drugs11 citations Open access
Semantic Scholar
A PHARMACOGENETIC STUDY OF ALDEHYDE OXIDASE I IN PATIENTS TREATED WITH XK469
J. Ramírez, Tae Won Kim, Wan-Qing Liu, J. Myers +9 more
2014Pharmacogenetics & Genomics9 citations Open access
Semantic Scholar
A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS).
G. Schwartz, W. Tap, L. Qin, M. Livingston +16 more
20129 citations
Semantic Scholar
Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations
J. Bruce, David Geary, B. de las Heras, A. Soto +5 more
20088 citations
Semantic Scholar
Dose-intense preoperative chemotherapy with hypofractionated radiation for high-risk soft-tissue sarcoma (STS)
C. Ryan, A. Montag, S. Undevia, J. Hosenpud +3 more
20056 citations
Semantic Scholar
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT)
P. O'Donnell, A. Artz, S. Undevia, J. Hart +1 more
20084 citations
Semantic Scholar
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
E. Posadas, S. Undevia, E. Manchen, J. Wade +4 more
2006Cancer Biology & Therapy4 citations
Semantic Scholar
Short Communication: R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9
Peng-Yong Wei, Tae Won Kim, S. Undevia, F. Innocenti +1 more
2009European Journal of Cancer3 citations Open access
Semantic Scholar
A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic αvβ3 and αvβ5 integrin antagonist, in patients with advanced solid malignancy.
S. Undevia, L. Janisch, W. Stadler, S. M. Wittemer +1 more
2006Journal of Clinical Oncology3 citations
Semantic Scholar
A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic {alpha}v{beta}3 and {alpha}v{beta}5 integrin antagonist, in patients with advanced solid malignancy
S. Undevia, L. Janisch, W. Stadler, S. M. Wittemer +1 more
20063 citations
Semantic Scholar
Role of HNF‐1α in the regulation of UGT1A1, UGT1A9 and UGT2B7 MRNA expression
S. Mirkov, Federico Innocenti, Wan-Qing Liu, Pei-Xian Chen +4 more
20053 citations
Semantic Scholar
Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS).
R. Chugh, K. Griffith, B. Brockstein, S. Undevia +2 more
20122 citations
Semantic Scholar
A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies
T. Gangadhar, E. Cohen, L. Janisch, L. House +5 more
20082 citations
Semantic Scholar
Phase I study of rapamycin (R) in combination with CYP3A4 modifier, ketoconazole (K), in patients with advanced malignancies.
E. W. Cohen, Kristin Moshier, Federico Innocenti, M. Kocherginsky +5 more
2006Journal of Clinical Oncology2 citations
Semantic Scholar
A dose-escalation study of the quinoxaline antitumor agent R(+)XK469 (XK) in patients with refractory solid tumors
E. Sprague, S. Undevia, F. Innocenti, J. Ramírez +6 more
20042 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Ratain×29
Invite
M. Ratain — researcher profile on SciRah
J. Ramírez×14
Invite
J. Ramírez — researcher profile on SciRah
F. Innocenti×11
Invite
F. Innocenti — researcher profile on SciRah
L. Janisch×11
Invite
L. Janisch — researcher profile on SciRah

×7

Invite

T. Karrison — researcher profile on SciRah

Invite

S. Schuetze — researcher profile on SciRah

Invite

R. Schilsky — researcher profile on SciRah

Invite

L. House — researcher profile on SciRah

Invite

M. Maitland — researcher profile on SciRah

Invite

Soma Das — researcher profile on SciRah

M. Livingston×5

Invite

M. Livingston — researcher profile on SciRah

Invite

W. Stadler — researcher profile on SciRah